Weight loss of about 25 kilograms! Novo Nordisk A/S Sponsored ADR Class B(NVO.US) announces the results of the Phase 3 trial of long-acting insulin.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) announced a subgroup analysis of the phase 3 REDEFINE 1 trial at the 2025 European Association for the Study of Diabetes (EASD) annual meeting on September 17th. This analysis evaluated the efficacy and safety of once-weekly 2.4 mg cagrilintide monotherapy combined with lifestyle intervention in adults with obesity or overweight without diabetes but with weight-related comorbidities. The analysis showed that patients in the cagrilintide group had an average weight loss of approximately 12.5 kilograms. Based on these results, Novo Nordisk A/S Sponsored ADR Class B plans to initiate the RENEW phase 3 clinical trial for cagrilintide in the fourth quarter of this year. According to the press release, the trial results announced are the first phase 3 clinical trial data for a long-acting amylin analog as monotherapy for obesity. Cagrilintide is a next-generation long-acting amylin analog that mimics naturally occurring amylin in the body, with a mechanism of action different from currently approved GLP-1-based weight-loss therapies. Novo Nordisk A/S Sponsored ADR Class B is evaluating cagrilintide as a once-weekly subcutaneous injection (recommended dose 2.4 mg) for the treatment of overweight or obese adults.